In surprising setback, combo of Roche’s Tecentriq and chemo fails to help patients with triple-negative breast cancer

Roche broke ground last year when they secured the first FDA approval for a checkpoint therapy in triple-negative breast cancer, a notoriously difficult-to-treat indication that has been passed over by the wave of targeted therapies.